Dr Daniel Forton, consultant hepatologist at St George’s University Hospitals NHS Foundation Trust, London, reviews the treatment of hepatitis C, especially Direct Acting Antiviral regimes and the importance of real-world data to inform optimal selection of treatments for specific patient groups. He concludes that real-world data suggest there is still a need to tailor treatment duration with the addition of ribavirin in certain situations with certain regimes to optimise efficacy.
Real-world effectiveness and safety data in HCV therapy
Consultant Hepatologist, St George’s University Hospitals NHS Foundation Trust, London
50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.